Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Participate in the Guggenheim Oncology Conference 2022
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Fourth-Quarter and Full-Year 2021 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Second-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Provides U.S. and Japan Regulatory Update for Gefapixant
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Frank Clyburn to Leave Merck
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
ADDING and REPLACING European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
European Commission Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Issues $1 Billion Inaugural Sustainability Bond
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Prices $8.0 Billion Debt Offering
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.